These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32787869)

  • 1. Reducing delays to multidrug-resistant tuberculosis case detection through a revised routine surveillance system.
    Doulla BE; Squire SB; MacPherson E; Ngadaya ES; Mutayoba BK; Langley I
    BMC Infect Dis; 2020 Aug; 20(1):594. PubMed ID: 32787869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine surveillance for the identification of drug resistant Tuberculosis in Tanzania: A cross-sectional study of stakeholders' perceptions.
    Doulla BE; Squire SB; MacPherson E; Ngadaya ES; Mutayoba BK; Langley I
    PLoS One; 2019; 14(2):e0212421. PubMed ID: 30794620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.
    van Kampen SC; Susanto NH; Simon S; Astiti SD; Chandra R; Burhan E; Farid MN; Chittenden K; Mustikawati DE; Alisjahbana B
    PLoS One; 2015; 10(6):e0123536. PubMed ID: 26075722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?
    Timire C; Takarinda KC; Harries AD; Mutunzi H; Manyame-Murwira B; Kumar AMV; Sandy C
    Trans R Soc Trop Med Hyg; 2018 Jun; 112(6):285-293. PubMed ID: 29992299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct detection of Mycobacterium tuberculosis and drug resistance in respiratory specimen using Abbott Realtime MTB detection and RIF/INH resistance assay.
    Tam KK; Leung KS; To SW; Siu GK; Lau TC; Shek VC; Tse CW; Wong SS; Ho PL; Yam WC
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):118-124. PubMed ID: 28780247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis.
    Page AL; Ardizzoni E; Lassovsky M; Kirubi B; Bichkova D; Pedrotta A; Lastrucci C; de la Tour R; Bonnet M; Varaine F
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1078-83, i-iii. PubMed ID: 26260829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application value of Xpert MTB/RIF in diagnosis of spinal tuberculosis and detection of rifampin resistance].
    Jin YH; Shi SY; Zheng Q; Shen J; Ying XZ; Wang YF
    Zhongguo Gu Shang; 2017 Sep; 30(9):787-791. PubMed ID: 29455477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complexities of Xpert® MTB/RIF interpretation.
    Lippincott CK; Miller MB; Van Rie A; Weber DJ; Sena AC; Stout JE
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):273-5. PubMed ID: 25686132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
    Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues.
    Polepole P; Kabwe M; Kasonde M; Tembo J; Shibemba A; O'Grady J; Kapata N; Zumla A; Bates M
    Int J Mycobacteriol; 2017; 6(1):87-93. PubMed ID: 28317811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses.
    Kendall EA; Kamoga C; Kitonsa PJ; Nalutaaya A; Salvatore PP; Robsky K; Nakasolya O; Mukiibi J; Isooba D; Cattamanchi A; Kato-Maeda M; Katamba A; Dowdy DW
    PLoS One; 2019; 14(7):e0220251. PubMed ID: 31339935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPA or GeneXpert in the diagnosis of multidrug-resistant tuberculosis.
    Mindru R; Spinu V; Popescu O
    Pneumologia; 2016; 65(2):76-80. PubMed ID: 29539256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.